Research programme: small-molecule therapeutics - Mavupharma
Alternative Names: MAVU 104; STING activators - MavupharmaLatest Information Update: 28 Dec 2021
Price :
$50 *
At a glance
- Originator Mavupharma
- Class Anti-infectives; Antineoplastics; Small molecules
- Mechanism of Action STING1 protein inhibitors; STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Cancer in USA (PO)
- 28 Dec 2021 No recent reports of development identified for research development in Infections in USA (PO)
- 15 Jul 2019 Mavupharma has been acquired by AbbVie